CLAIMS

1. A combination of (i) an SGLT 2 inhibitor selected from the group consisting of (1S)-1,5-anhydro-1-[3-(4-ethoxybenzyl)-6-methoxy-4-methylphenyl]-1-thio-D-glucitol, a pharmaceutically acceptable salt thereof, or a hydrate of the compound or salt, and (ii) an antihypertensive drug selected from the group consisting of lisinopril and valsartan, or a pharmaceutically acceptable salt thereof, or a hydrate of the compound or salt for use in the treatment of a disease involving at least hypertension or diabetes mellitus as a risk factor of cardiovascular events.

2. The combination according to claim 1, wherein (i) and (ii) are either simultaneously or separately to be administered to a patient in need thereof.

3. The combination according to claim 1 or 2, wherein the disease is hypertension.

4. The combination according to claim 1 or 2, wherein the disease is diabetes mellitus, a disease associated with diabetes mellitus, or a complication of diabetes mellitus.

5. The combination according to any one of claims 1 to 4, wherein the disease involves manifestations of both diabetes mellitus and hypertension.

6. The combination according to any one of claims 1 to 5, wherein the disease is diabetic nephropathy.

7. The combination according to any one of claims 1 to 5, wherein the disease further involves an observable lowered renal function.

8. The combination according to claim 1 to enhance a hypotensive action of the antihypertensive drug.

9. The combination according to claim 1 to enhance the effect of the SGLT 2 inhibitor in the treatment of diabetes mellitus, a disease associated with diabetes mellitus, or a complication of diabetes mellitus.

10. The combination according to claim 1 to enhance the effect of the SGLT 2 inhibitor in the treatment of diabetic nephropathy.

11. The use of a combination of (i) an SGLT 2 inhibitor selected from the group consisting of (1S)-1,5-anhydro-1-[3-(4-ethoxybenzyl)-6-methoxy-4-methylphenyl]-1-thio-D-glucitol, a pharmaceutically acceptable salt thereof, or a hydrate of the compound or salt, and (ii) an antihypertensive drug selected from the group consisting of lisinopril and valsartan, or a pharmaceutically acceptable salt thereof, or a hydrate of the compound or salt, in the manufacture of a medicament for the treatment of a disease involving at least hypertension or diabetes mellitus as a risk factor of cardiovascular events.

12. The use of an SGLT 2 inhibitor selected from the group consisting of (1S)-1,5-anhydro-1-[3-(4-ethoxybenzyl)-6-methoxy-4-methylphenyl]-1-thio-D-glucitol, a pharmaceutically acceptable salt thereof, or a hydrate of the compound or salt in the manufacture of a first medicament and the use of an antihypertensive drug selected from the group consisting of lisinopril and valsartan, or a pharmaceutically acceptable salt thereof, or a hydrate of the compound or salt in the manufacture of a second medicament, both medicaments for the treatment of a disease involving at least hypertension or diabetes mellitus as a risk factor of cardiovascular events whereby each medicament is to be administered simultaneously or separately

CLAIMS

1. A medicament for treating a disease selected from hypertension, diabetes mellitus, a disease associated with diabetes mellitus, a complication of diabetes mellitus,a disease involving manifestations of both diabetes mellitus and hypertension, and a disease that further involves a lowered renal function resulting from any one of the diseases mentioned above, which is characterized by a combination of (i) an SGLT 2 inhibitor selected from the group consisting of

(1S)-1,5-anhydro-1-[3-(4-ethoxybenzyl)-6-methoxy-4-methylphenyl]-1-thio-D-glucitol, a pharmaceutically acceptable salt thereof, or a hydrate of the compound or salt, and (ii) an antihypertensive drug selected from the group consisting of lisinopril and valsartan, or a pharmaceutically acceptable salt thereof, or a hydrate of the compound or salt.

2. The medicament according to claim 1,
wherein (i) and (ii) are either simultaneously or separately administered to a patient in need thereof.

3. Use of a combination of (i) an SGLT 2 inhibitor selected from the group consisting of
(1S)-1,5-anhydro-1-[3-(4-ethoxybenzyl)-6-methoxy-4-methylphenyl]-1-thio-D-glucitol, a pharmaceutically acceptable salt thereof, or a hydrate of the compound or salt, and (ii) an antihypertensive drug selected from the group consisting of lisinopril and valsartan, or a pharmaceutically acceptable salt thereof, or a hydrate of the compound or salt,
in the manufacture of a medicament for treating a disease selected from hypertension, diabetes mellitus, a disease associated with diabetes mellitus, a complication of diabetes

mellitus,a disease involving manifestations of both diabetes mellitus and hypertension, and a disease that further involves a lowered renal function resulting from any one of the diseases mentioned above .

4. The use according to claim 3, wherein (i) and (ii) are either simultaneously or separately administered to a patient in need thereof.

5. The use according to claim 3 or 4, wherein the disease is hypertension.

6. The use according to claim 3 or 4, wherein the disease is diabetes mellitus, a disease associated with diabetes mellitus, or a complication of diabetes mellitus.

7. The use according to claim 3 or 4, wherein the disease involves manifestations of both diabetes mellitus and hypertension.

8. The use according to claim 3 or 4, wherein the disease is diabetic nephropathy.

9. The use according to any one of claims 3 to 7, wherein the disease further involves an observable lowered renal function.